Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 11/20 | 0.69 |
| ▸ | USP1 | O94782 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | BRD2 | P25440 | 3/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17555411 | 1.00 | MAPK1 (0.69) | MAPK1USP1JAK2BRD4BRD2 | |
| Trifluoroacetic Acid SCHEMBL16213533 | 0.92 | MAPK1 (0.66) | MAPK1USP1 | |
| Trifluoroacetic Acid SCHEMBL16213530 | 0.92 | MAPK1 (0.66) | MAPK1USP1 | |
| SCHEMBL22382060 | 0.82 | MAPK1 (1.00) | MAPK1 | |
| SCHEMBL20560434 | 0.81 | MAPK1 (1.00) | MAPK1CYP3A4 | |
| SCHEMBL16224846 | 0.81 | MAPK1 (1.00) | MAPK1CYP3A4 | |
| SCHEMBL16224927 | 0.79 | MAPK1 (0.73) | MAPK1USP1 | |
| SCHEMBL16213472 | 0.77 | MAPK1 (0.48) | MAPK1USP1JAK2BRD4BRD2 | |
| SCHEMBL16213473 | 0.77 | MAPK1 (0.48) | MAPK1USP1JAK2BRD4BRD2 | |
| SCHEMBL16224842 | 0.77 | MAPK1 (1.00) | MAPK1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759805-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759805-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-2991654-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180319804-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-11-08 | — | — | US | disclosed |
| US-10065967-B2 | Compounds that are ERK inhibitors | Merck, Sharp & Dohme Corp. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20170320882-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320882-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-9745307-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745307-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160068532-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068532-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2014179154-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759805-B2 | Compounds that are ERK inhibitors | MAPK1, MAPK4, MAP3K1 | MAPK1 1/4885USP1 2869/4885JAK2 273/4885 |
| US-20180319804-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | MAPK1 1/4885USP1 2260/4885JAK2 324/4885 |
| US-20170320882-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | MAPK1 1/4885USP1 2260/4885JAK2 324/4885 |
| US-10065967-B2 | Compounds that are ERK inhibitors | MAPK1, MAPK4, MAP3K1 | MAPK1 1/4885USP1 2869/4885JAK2 273/4885 |
| US-20160068532-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAP3K20, MAPK6 | MAPK1 1/4885USP1 3174/4885JAK2 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.